Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 12/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 12/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 11/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 11/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 11/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 11/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 9/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | GABRE | P78334 | 1/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.39 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL28101298 | 0.92 | PLAT (0.36) | GABRG2GABRB3GABRA1GABRA3GABRA2 | |
| SCHEMBL2210189 | 0.78 | — | — | |
| SCHEMBL11192022 | 0.76 | GABRP (0.34) | GABRG2GABRB3GABRA1GABRA3GABRA2 | |
| SCHEMBL159836 | 0.74 | GABRA1 (0.39) | GABRG2GABRB3GABRA1GABRA3GABRA2 | |
| SCHEMBL28905563 | 0.74 | — | — | |
| SCHEMBL19100124 | 0.73 | MAPT (0.42) | ALDH1A1LMNA | |
| SCHEMBL21873273 | 0.73 | GPR119 (0.50) | — | |
| SCHEMBL3896577 | 0.72 | CES2 (0.31) | — | |
| SCHEMBL6816234 | 0.72 | NAMPT (0.50) | — | |
| SCHEMBL18681468 | 0.72 | TRPA1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110483424-A | A kind of preparation method of 1-H-1,2,3- triazole -4- carboxylic acid tert-butyl ester | SHANGHAI RAISE CHEMICAL TECH CO LTD | 2019-11-22 | — | — | CN | claimed |
| US-12264138-B2 | Process for the preparation of microbiocidal oxadiazole derivatives | SYNGENTA CROP PROTECTION AG (CH) | 2025-04-01 | — | — | US | disclosed |
| CN-116157154-A | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-115151538-A | Macrocyclic compounds, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2022-10-04 | — | — | CN | disclosed |
| CN-114667289-A | Heteroaryl plasma kallikrein inhibitors | 武田药品工业有限公司 | 2022-06-24 | — | — | CN | disclosed |
| US-20220194907-A1 | PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2022-06-23 | — | — | US | disclosed |
| US-11358957-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2022-06-14 | — | — | US | disclosed |
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-07 | — | — | US | disclosed |
| CN-112135825-A | Plasma kallikrein inhibitors and uses thereof | 夏尔人类遗传性治疗公司 | 2020-12-25 | — | — | CN | disclosed |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200277287-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-09-03 | — | — | US | disclosed |
| CN-110483424-A | A kind of preparation method of 1-H-1,2,3- triazole -4- carboxylic acid tert-butyl ester | SHANGHAI RAISE CHEMICAL TECH CO LTD | 2019-11-22 | — | — | CN | disclosed |
| WO-2019178129-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | GABRG2 2939/4885GABRB3 3401/4885GABRA1 3085/4885 |
| US-12264138-B2 | Process for the preparation of microbiocidal oxadiazole derivatives | CYP51A1, MPO, NOX5 | GABRG2 1992/4885GABRB3 1868/4885GABRA1 1822/4885 |
| US-20200277287-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, NOX1, ARG2 | GABRG2 1845/4885GABRB3 1327/4885GABRA1 1518/4885 |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | GABRG2 2939/4885GABRB3 3401/4885GABRA1 3085/4885 |
| US-11358957-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG2 | GABRG2 1845/4885GABRB3 1327/4885GABRA1 1518/4885 |
| US-20220194907-A1 | PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES | CYP51A1, MPO, NOX5 | GABRG2 1992/4885GABRB3 1868/4885GABRA1 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.